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The peptide somatostatin is one of many neuroactive agents that inﬂuence retinal physiology. It is synthesized primarily in a
subclass of amacrine cells and believed to function as a neurotransmitter, neuromodulator or trophic factor. The cloning of the
somatostatin receptors (sst1–5) in the early nineties provided the appropriate tools for the study of ssts in many tissues, including the
retina. In this review, emphasis is given to recent studies that have provided signiﬁcant information on the functional role of so-
matostatin in retinal circuitry and the retinal pigment epithelium. The important role of somatostatin in retinal disease therapeutics
is also discussed.
 2003 Elsevier Science Ltd. All rights reserved.
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The neuropeptide somatostatin (somatotropin release
inhibitory factor, SRIF) is a cyclic tetradecapeptide,
which is widely distributed in the peripheral and central
nervous system (Brazeau et al., 1973; Epelbaum, 1986).
It mediates a diverse number of physiological actions by
interacting with speciﬁc receptors in the plasma mem-
brane (Thermos, He, Wang, Margolis, & Reisine, 1989;
Thermos & Reisine, 1988). Five SRIF receptor subtypes
have been cloned, namely sst1–5 (Bruno, Xu, Song, &
Berelowitz, 1992; Meyerhof, Wylfsen, Schonrock, Fehr,
& Richter, 1992; OCarroll, Lolait, Konig, & Mahan,
1992; Yamada et al., 1992). The sst2 has been identiﬁed
in mouse and rat to exist as two-splice variants sst2A and
sst2B (Schindler et al., 1998; Vanetti, Kouba, Wang,
Vogt, & Hollt, 1992). These receptors are expressed
diﬀerentially in diﬀerent tissues, coupled to diﬀerent G-
proteins and modulate the actions of diverse second
messengers (Florio & Schettini, 1996; Hoyer et al., 1995;
Patel & Srikant, 1994; Reisine & Bell, 1995; Tannen-
baum & Epelbaum, 2000).* Tel.: +30-2810-394533; fax: +30-2810-394530.
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doi:10.1016/S0042-6989(03)00169-XSomatostatin is one of many neuroactive substances
that inﬂuence retinal physiology. Its presence has been
detected with mRNA, radioimmunoassay, and immuno-
histochemistry techniques (Akopian, Johnson, Gabriel,
Brecha, & Witkovsky, 2000; Larsen, Bersani, Olcese,
Holst, & Moller, 1990; Rickman, Blanks, & Brecha,
1996; Rorstad, Brownstein, & Martin, 1979; Rorstad,
Senternman, Hoyte, & Martin, 1980; Sagar, Marshall, &
Landis, 1985; Sagar, Rorstad, Landis, Arnold, & Mar-
tin, 1982; Sagar & Marshall, 1988; Sagar, 1987; Shapiro,
Kronheim, & Pinistone, 1979; Spira, Schimizu, &
Rorstad, 1984; Tornqvist, Uddman, Sundler, & Ehinger,
1982; White, Chalupa, Johnson, & Brecha, 1990; Ya-
mada et al., 1980; Yamaguchi, Gaur, Spira, & Turner,
1990). SRIF is localized primarily in wide-ﬁeld amacrine
cells with processes that ramify in the inner plexiform
layer (IPL), in cells of the ganglion cell layer (GCL) and
in neurons in the inner nuclear layer (INL), some of
which are probably interplexiform cells (Akopian et al.,
2000; Larsen et al., 1990; Rickman et al., 1996; Sagar
et al., 1985; Sagar & Marshall, 1988; Sagar, 1987; Torn-
qvist et al., 1982; White & Chalupa, 1991; White et al.,
1990).
Electrophysiological studies have supported that
SRIF may function as a neurotransmitter, neuromodu-
lator or trophic factor (Adolph, 1989; Akopian et al.,
2000; Petrucci, Resta, Fieni, Bigiani, & Bagnoli, 2001;served.
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the spontaneous ﬁring and light-evoked activity of
ganglion cell activity in turtle retina (Adolph, 1989). In
an extensive electrophysiological study Zalutsky and
Miller (1990) also detected a general excitation on rat
ganglion cells, in addition to an increase in the ‘‘signal-
to-noise ratio’’ deﬁned as the ratio of light-evoked to
spontaneous spiking, and a shift in center-surround
balance towards a more dominant center. The authors
suggested that SRIF acts at diﬀerent neurons of the
retinal circuitry (direct action on ganglion and amacrine
cells) to produce the above mentioned actions. In a more
recent investigation, Akopian et al. (2000) presented
evidence to support somatostatins modulation of volt-
age-gated Kþ and Caþþ currents in photoreceptors,
while Petrucci et al. (2001) supported somatostatins
modulation of potassium current and calcium inﬂux in
isolated rod bipolar cells of the rabbit.
The purpose of this review is to summarize experi-
ments that have been performed during the last decade
and have shed some light on the functional role of so-
matostatin in retinal circuitry and its possible thera-
peutic applications in retinal disease. In particular,
emphasis is given to the immunohistochemistry studies
performed over the last ﬁve years, the results of which
provided signiﬁcant information on the localization of
the somatostatin receptor subtypes in retinal neurons
and subsequently their function.2. Somatostatin receptors in the retina
Prior to the cloning of the somatostatin receptors,
pharmacological studies had shown the presence of so-
matostatin binding sites in the retina. Radioligand
binding experiments were performed in the retina initially
in the mid eighties. Speciﬁc binding sites for [125I]Tyr11
somatostatin-14 were characterized in the cytosol frac-
tion of the pig retina (Colas, Arilla, & Prieto, 1986).
Subsequent studies employing either autoradiography or
membrane binding techniques and the radioligands
[125I]Tyr11 somatostatin-14, [125I]Tyr0, DTrp8]somatost-
atin-14, [125I] [Leu8, D-Trp22, Tyr25]somatostatin-28,
and [125I] SMS204-090 provided evidence of high aﬃnity
binding sites for somatostatin in mouse (Kossut, Aldrich,
Yamada, & Pinto, 1990; Kossut, Yamada, Aldrich, &
Pinto, 1989), ovine (Colas, Valencia, Prieto, & Arilla,
1992) and rabbit retinas (Liapakis, Politou, & Thermos,
1993; Liapakis & Thermos, 1992; Vasilaki, Hatzilaris,
Liapakis, Georgoussi, & Thermos, 1996), as well as in the
rat retina during development (Bodenant, Leroux,
Gonzalez, & Vaudry, 1991; Ferriero, 1992). Pharmaco-
logical and biochemical studies in the ovine and rabbit
retinas presented evidence showing that the somatostatin
receptors are coupled to G-proteins and inﬂuence ade-nylate cyclase activity (Colas et al., 1992; Liapakis &
Thermos, 1992).
The cloning of ﬁve somatostatin receptor subtypes
(Bruno et al., 1992; Meyerhof et al., 1992; OCarroll
et al., 1992; Yamada et al., 1992) created new avenues
for the study of somatostatin receptors and their phy-
siological function in many tissues including the retina.
Mori, Ahara, and Shimizu (1997) performed the ﬁrst
reverse transcription-polymerase chain reaction (RT-
PCR) studies in rat ocular tissues and reported the
presence of all ssts in the retina with the sst2 subtype
being the predominant. Johnson, Wu, Wong, Walsh,
and Brecha (1999) subsequently examined the presence
of mRNA of the two-splice variants of the sst2 receptor
in rat retina and reported the expression of sst2A but not
the sst2B receptors. In the rabbit retina, sst1 was reported
to be the predominant subtype, but moderate to low
levels of the other receptor subtypes were also expressed
(Cristiani et al., 2000). Most recently, all ssts were de-
tected in mouse retina with high levels of sst2 and sst4
mRNA and moderate levels of sst1 and sst5 mRNA
(Cristiani, Petrucci, Dal Monte, & Bagnoli, 2002). In a
review by Van Hagen et al. (2000), sst1, sst2A, and sst3
mRNAs were reported to be also present in human
retina. In agreement with these data, sst1, sst2A, and sst3
mRNAs were also detected in the posterior pole, which
included the retina, in normal human eyes (Lambooij
et al., 2000). In addition, a study by Klisovic et al. (2001)
presented evidence to support the expression of genes
for all receptor subtypes (sst1–5) in normal human retina,
with the sst3 and sst5 genes being expressed only in the
retina, among the ocular tissues examined.
While the RT-PCR studies performed in the diﬀerent
species are limited, one can detect a consensus in the
expression of all subtypes in the mouse, rat, and rabbit
retinas with diﬀerences observed in the quantity of each
receptor (Cristiani et al., 2000, 2002; Mori et al., 1997).
In the human retina, there is agreement with respect to
the expression of sst1, sst2/sst2A, and sst3 subtypes. The
discrepancy in the presence or absence of the sst4 and
sst5 receptors may be due to the diﬀerent retinal prep-
arations employed, as well as the primer sequences used
for the RT-PCR studies (Klisovic et al., 2001; Lambooij
et al., 2000).
With the recent development of speciﬁc antibodies for
each receptor subtype, immunohistochemistry studies
have given important information on the identity and
localization of each receptor in retinal cells of diﬀerent
species.
2.1. sst1
Helboe and Moller (1999) ﬁrst reported the localiza-
tion of sst1 receptors in rat retina, using a rabbit poly-
clonal antiserum raised against fragments of the
C-terminal part of the human sst1 (Helboe, Moller,
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activity was found to be present in SRIF expressing
amacrine cells located in the INL, in displaced amacrine
cells in the GCL and in a small number of ganglion cells.
Cristiani et al. (2000) employed the sst1 antibody
produced by Helboe et al. (1997) and showed sst1
immunoreactivity in amacrine cells (non-tyrosine hy-
droxylase (TH)- and TH-immunoreactive), displaced
amacrines and in the GCL of the ventral rabbit retina.
Helboe and Moller (1999) did not observe sst1 immu-
noreactivity on TH-amacrine cells or their processes in
the rat retina. In agreement with the latter study, we did
not detect sst1 immunoreactivity in TH or ChAT im-
munoreactive processes located in the sublamina S1 of
the IPL. We employed a rabbit antiserum raised against
a peptide fragment (374–391) of the rsst1 receptor sub-
type (Schulz, Handel, Schreﬀ, Schmidt, & Hollt, 2000)
and detected sst1 immunoreactivity in cell processes
lengthening throughout the IPL in sublamina S1, in
blood vessels of the inner retina, and the retinal pigment
epithelium (RPE) of the rat (Vasilaki, Mouratidou,
Schulz, & Thermos, 2002). sst1 immunoreactivity was
reported in human retina to be localized in retinal
ganglion cells, the INL and the RPE (Van Hagen et al.,
2000). In an attempt to examine the somatostatin re-
ceptor gene expression and localization in human ocular
tissue (Klisovic et al., 2001), reported sst1 immunore-
activity in membranes of outer and inner segments of
rods and cones, and individual cells in the ONL, INL
and GCL. sst1 immunostain was also present in retinal
blood vessels, in cultured RPE cells, and human RPE
tissue. The antibody employed in the latter study was a
rabbit polyclonal antiserum raised against a peptide
antigen made of the N-terminal 57 amino acids of hsst1
(Albers et al., 2000).
2.2. sst2
A pharmacological study performed by Vasilaki et al.
(1996) suggested the presence of sst2 receptors in rabbit
retina, yet it was Johnson, Wong, Walsh, and Brecha
(1996, 1998) who ﬁrst showed the expression of the sst2A
receptor in neurons of the rabbit retina. These investi-
gators employed a polyclonal antibody raised against
the C-terminus of mouse sst2A (361–369) and indicated
sst2A receptor localization mainly in the plasma mem-
brane of rod bipolar cells and to sparsely occurring
wide-ﬁeld amacrine cells of the rabbit retina. Immuno-
staining in the rod bipolar cells was strongest in the axon
and axon terminals in lamina 5 of the IPL and was
weakest in the cell body and dendrites. Immunoreactive
amacrine cell bodies were located at the border of the
INL and the IPL. Also, in rabbit retina, Petrucci et al.
(2001) identiﬁed sst2A receptors in isolated rod bipolar
cells, while Fontanesi, Gargini, and Bagnoli (2000) re-
ported the postnatal development of sst2A expression inrod bipolar cells and amacrine cells, some of which were
TH positive. The antibodies employed in these last two
studies were the same, a sheep polyclonal antibody di-
rected against the amino acid sequence 347–366 of the
carboxy terminus of rat sst2A. This peptide sequence is
identical in rat, human and mouse sst2A receptors
(Schindler, Sellers, Humphrey, & Emson, 1997).
In the rat retina, sst2A immunoreactivity was localized
in the outer retina to cone photoreceptors, horizontal
cells and rod and cone bipolar cells, while in the inner
retina to TH-positive amacrine cells of medium to large
size (Johnson et al., 1999). The antibody employed was
the same as in the rabbit studies by Johnson et al.
(1998). Helboe and Moller (1999) employing a rabbit
polyclonal antibody raised against the C-terminal parts
of the human sst2 noted immunoreactivity in large
amacrine cells of the INL that also contained TH, in
inner segments of cone photoreceptors and in Muller
cell ﬁbers. sst2 immunoreactivity was not detected in
horizontal cells nor rod bipolar cells. Vasilaki, Gardette,
Epelbaum, and Thermos (2001) reported sst2A immuno-
reactivity in rod bipolar cells of the rat and rabbit reti-
nas, using a rabbit polyclonal antibody raised against
the amino acid sequence 355–369 of the rsst2A. Double
labeling experiments of sst2A and TH showed no colo-
calization in either species. In the mouse, sst2 immu-
noreactivity was localized to rod bipolar, horizontal and
TH- and glycine-containing amacrine cells (Cristiani
et al., 2002), employing the sheep polyclonal antibody
mentioned above (Schindler et al., 1997).
In human ocular tissue, sst2 immunostain was re-
ported in the outer and inner segments of rods and cones
and individual cells in the ONL, INL and GCL
(Klisovic et al., 2001). The morphology of the individual
cells (amacrine, rod bipolar cells, etc.) in the retinal
layers mentioned was not assessed. sst2 immunostain
was also detected in endothelial cells of blood vessels, as
well as on cell membranes and cytoplasm of individual
RPE cells in culture. A rabbit polyclonal antibody raised
against the N-terminal 45 amino acids of the sst2 was
employed. This amino acid sequence is common to both
sst2A and sst2B, and thus one could suggest the presence
of both splice variants of the sst2 receptor. Also, in
human retina sst2A immunoreactivity was reported in
the inner and outer nuclear and plexiform layers, as well
as the RPE (Van Hagen et al., 2000). These ﬁndings
were conﬁrmed by RT-PCR studies (Klisovic et al.,
2001; Van Hagen et al., 2000), as mentioned previously.
In the lower vertebrates, sst2A immunoreactivity was
localized to both inner and outer retina of the sala-
mander (Akopian et al., 2000), using the same antibody
employed by Johnson et al. (1998, 1999). Speciﬁcally,
sst2A immunoreactivity was observed in rod and cone
photoreceptors with prominent staining through out the
inner segment and synaptic terminals. sst2A immunore-
activity was also noted in bipolar and amacrine cell
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immunostain was reported in the GCL. In retinas of the
adult newt Pl. waltl, sst2A immunoreactivity was also
observed in rod bipolar, inner segments of the cone
photoreceptors and in the region corresponding to
connecting cilia of rods (Grigoryan, Vasilaki, Mastro-
dimou, & Thermos, 2003).
2.3. sst2B
There are not many reports supporting the presence
of sst2B in the retina. sst2B immunoreactivity was local-
ized to rod and cone photoreceptors of the rat, but not
the rabbit retina (Vasilaki et al., 2001). A rabbit poly-
clonal antibody raised against the peptide fragment of
the carboxy terminus [amino acids 329–343] of the rsst2B
was employed (Schulz et al., 2000). Other investigators
have reported the absence of the sst2B receptor subtype.
Petrucci et al. (2001) could not detect sst2B immunore-
activity in the rabbit retina using a rabbit antiserum
raised against the 15 terminal amino acids of the car-
boxy terminus of the rat sst2B plus an extra cysteine
residue at the amino terminal end (Schindler, Hum-
phrey, Lohre, & Friauf, 1999), while Johnson et al.
(1999) could not detect sst2B mRNA in the retina of the
rat. More recent ﬁndings have shown the presence of
sst2B in individual human RPE cell cultures (Papadaki,
Vasilaki, Tsilimbaris, Pallikaris, & Thermos, 2002). As
indicated above, Klisovic et al. (2001) reported sst2 im-
munoreactivity in RPE cultures that may be partly due
to sst2B.
2.4. sst3
sst3 immunoreactivity has not been localized in
mammalian retina, even though its mRNA was detected
by RT-PCR in rat (Mori et al., 1997) and human retina
(Klisovic et al., 2001; Van Hagen et al., 2000). sst3 im-
munostain was reported in the lower vertebrate newt
(Pleurodeles waltliiMichan) to be most intensely present
in the inner segments of cones and in cilia of rods
(Grigoryan et al., 2003).
2.5. sst4
We recently examined sst4 immunoreactivity in the rat
retina. It was conﬁned to multistratiﬁed processes of the
IPL, the plasma membrane, the cytoplasm of cell bodies
and clusters of long processes in the GCL. Optic nerve
ﬁbers of the rat retina were also selectively immuno-
stained for sst4. Colocalization of sst4 and the ganglion
cell marker MAP-1A was observed in both cell bodies
and processes of the GCL and processes in the IPL. This
colocalization signiﬁes that the sst4 expression is re-
stricted in ganglion cell bodies, the dendritic ﬁeld and
axons, and not on amacrine cell processes in the IPL orthe cell bodies of displaced amacrine cells in the GCL
(Vasilaki et al., 2002).
Brecha, Vila, and Allen (2002) in a recent report
presented evidence of speciﬁc sst4 immunoreactivity in
the mouse and rat retina to be localized to multistrati-
ﬁed ganglion cells and in processes in all regions of the
IPL. Also, sst4 immunoreactivity was localized to cal-
binding (CaBP)-IR and CaBP-non-IR cells in the GCL
of the mouse retina (Cristiani et al., 2002). RT-PCR
data also support the presence of sst4 in rat (Mori et al.,
1997), mouse (Cristiani et al., 2002), and human retina
(Klisovic et al., 2001).
2.6. sst5
sst5 immunoreactivity has not been reported in the
retina of any species even though low sst5 mRNA levels
were detected by RT-PCR in rat (Mori et al., 1997),
mouse (Cristiani et al., 2002), and human retina
(Klisovic et al., 2001). We have data to support sst5
immunoreactivity in human RPE cell cultures (Vasilaki
et al., unpublished data).
2.7. Summary
An attempt was made to present the most updated
evidence on the presence and localization of somatost-
atin receptors in the retina. The antibodies employed by
the diﬀerent investigators and their ﬁndings regarding
the localization of each receptor subtype were compared
(Fig. 1, Table 1). An overall general consensus on the
localization of the receptors is observed in the diﬀerent
species studied.
Due to the earlier availability of the sst2/sst2A anti-
bodies a larger number of investigations focused on
these receptors. Most of these studies support the pres-
ence of sst2A in rod bipolar cells in all species studied
(Akopian et al., 2000; Cristiani et al., 2002; Fontanesi
et al., 2000; Johnson et al., 1996, 1998; Johnson, Rick-
man, & Brecha, 2000; Petrucci et al., 2001; Vasilaki et al.,
2001), with the exception of the study by Helboe and
Moller (1999). Minor discrepancies are apparent in re-
sults obtained within the same group and between
groups. Thus, Johnson et al. (1999) reported the pres-
ence of sst2A in cone photoreceptors, cone bipolar and
horizontal cells of the rat but not the rabbit retina
(Johnson et al., 1998), employing the same conditions.
Also, Vasilaki et al. (2001) reported the presence of sst2B
in rat, but not rabbit, rod and cone photoreceptors.
These discrepancies allude to species diﬀerences.
The major discrepancies between groups pertain to
the presence (Cristiani et al., 2000) or absence (Helboe &
Moller, 1999; Vasilaki et al., 2002) of sst1 immuno-
reactivity in TH-containing amacrine cells and the pres-
ence (Cristiani et al., 2002; Fontanesi et al., 2000;
Helboe & Moller, 1999; Johnson et al., 1999) or absence
Fig. 1. Mapping of ssts in the retina. This ﬁgure summarizes the results of diﬀerent investigations on the localization of somatostatin receptor
subtypes in retinal circuitry and the RPE. A panel is also included to depict the localization of somatostatin neurons. RPE, retinal pigment epi-
thelium, ONL, outer nuclear layer, OPL, outer plexiform layer, INL, inner nuclear layer, IPL, inner plexiform layer, GCL, ganglion cell layer, R,
rod, RBC, rod bipolar cell, C, cone, CBC, cone bipolar cell, H, horizontal cell, V, vessel, AC, non-TH amacrine cell, TH, tyrosine hydroxylase
containing amacrine cell, D-AC, displaced amacrine cell, GC, ganglion cell, Ca-BP, calbindin expressing ganglion cell, M, Mueller cell. (1) Helboe
and Moller (1999), (2) Johnson et al. (1998), (3) Johnson et al. (1999), (4) Fontanesi et al. (2000), (5) Grigoryan et al. (2003), (6) Van Hagen et al.
(2000), (7) Cristiani et al. (2000), (8) Klisovic et al. (2001), (9) Petrucci et al. (2001), (10) Vasilaki et al. (2001), (11) Brecha et al. (2002), (12) Vasilaki
et al. (2002), (13) Cristiani et al. (2002), (14) Akopian et al. (2000), (15) Papadaki et al. (2002), (16) Sagar and Marshall (1988), (17) White et al.
(1990), (18) Larsen et al. (1990).
Table 1
Antibodies used for the locallization of ssts in the retina
sst Antigen Reference
sst1 C-terminus 374–391 (human) Cristiani et al. (2000), Helboe and Moller (1999), Helboe et al.
(1997)
C-terminus 374–391 (rat) Schulz et al. (2000), Vasilaki et al. (2002)
N-terminus 1–57 (human) Albers et al. (2000), Klisovic et al. (2001)
sst2 N-terminus 1–45 (human) Albers et al. (2000), Klisovic et al. (2001)
sst2A C-terminus 361–369 (mouse) Akopian et al. (2000), Johnson et al. (1998, 1999)
C-terminus 347–366 (mouse, rat, human) Fontanesi et al. (2000), Petrucci et al. (2001), Schindler et al.
(1997)
C-terminus 330–369 (human) Helboe et al. (1997)
C-terminus 355–369 (rat) Schulz et al. (2000), Vasilaki et al. (2001)
sst2B C-terminus 329–343 (rat) Schulz et al. (2000), Vasilaki et al. (2001)
C-terminus 329–343 +cys (rat) Petrucci et al. (2001), Schindler et al. (1999)
sst3 C-terminus 417–428 (rat) Grigoryan et al. (2003)
sst4 C-terminus 362–384 (mouse) Cristiani et al. (2002), Schulz et al. (2000), Vasilaki et al. (2002)
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ization of sst2A and TH. While some of the discrepancies
may be due to the diﬀerent antibodies employed, onemust
take into account that diﬀerences were also observed
among investigators employing the exact same antibody
in the same species (Cristiani et al., 2000; Helboe &Moller, 1999). It is the opinion of the author that these
discrepancies are due to minor technical diﬀerences that
are diﬃcult to pinpoint. The major issue involving the
function of these receptors will be elucidated with direct
pharmacological studies examining the eﬀect of sst1 and
sst2 selective agonists on the release of dopamine.
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circuitry
The presence of somatostatin receptors in photore-
ceptors, rod bipolar and ganglion cells suggests that
somatostatin synthesized and released by a subcategory
of amacrine cells may act at a distance in a paracrine
fashion, and may inﬂuence the release of glutamate the
major neurotransmitter of these retinal cell types. More
speciﬁcally, Akopian et al. (2000) reported the soma-
tostatin modulation of voltage-gated Kþ and Ca2þ
currents through activation of sst2A receptors present in
the photoreceptors of the salamander retina, and sug-
gested a possible role for somatostatin in the regulation
of glutamate transmitter release from photoreceptors.
Also, studies performed on isolated rod bipolar cells of
the rabbit retina showed SRIF and octreotide to mod-
ulate Ca2þ-voltage-dependent Kþ channels by activating
sst2 receptors (Petrucci et al., 2001). Somatostatin was
also shown to inhibit calcium inﬂux into rat bipolar cell
axonal terminals (Johnson, Caravelli, & Brecha, 2001).
The sst2 receptor couples to G0a, localized in the IPL in
the rabbit retina (Vasilaki, Georgoussi, & Thermos,
2003). This relationship may be instrumental in somato-
statins modulation of the ion channels found on rod
bipolar cells and the subsequent neurotransmitter re-
lease. Earlier electrophysiological studies have shown
that G0a2 couples SRIF receptors to Ca
2þ channels
(Kleuss et al., 1992). No studies have been reported to
date, however, to substantiate a direct regulation of
glutamate release by somatostatin in the retina.
The presence of sst1 and sst2 on somatostatin and TH
expressing amacrine cells in the rat retina, respectively,
suggests a role for somatostatin in the regulation of its
own release as well as that of dopamine. To directly
study the former, namely whether sst1 functions as an
autoreceptor in the retina, we have conducted functional
studies ex vivo in retinal explants to measure the eﬀect of
the sst1 selective agonist CH275 on somatostatin release.
We have preliminary data depicting a decrease of SRIF
release upon CH275 activation, suggesting an autore-
ceptor function for sst1 (N. Mastrodimou, unpublished
data).
As presented above, diﬀerent groups have shown the
presence (Helboe & Moller, 1999; Johnson et al., 1998,
1999) or absence (Johnson et al., 1998; Vasilaki et al.,
2001) of sst2 and sst2A colocalization with TH, yet no
functional data have been presented to date to support a
direct regulation of dopamine release by somatostatin in
the retina.
We recently focused our research interests to the pu-
tative somatostatin–nitric oxide interactions for the
following reasons. In brain, SRIF is colocalized with
NADPH-diaphorase (a marker for nitric oxide synthase,
Dawson, Bredt, Fotuhi, Hwang, & Snyder, 1991) in
medium sized aspiny neurons of the striatum (Vincent &Johansson, 1983), but there are no reports to suggest
that the two systems interact functionally. NADPH-
diaphorase is present in all retinal cell types, including
subpopulations of amacrine cells. While colocalization
of SRIF with NO in amacrine cells was never observed
(Koistinaho & Sagar, 1995), as was the case in the
striatum (Vincent & Johansson, 1983), the sst2A receptor
appears to be localized in most retinal cells (Akopian
et al., 2000; Helboe & Moller, 1999; Johnson et al., 1998,
1999) that are known to express nitric oxide synthase
(NOS) or NADPH-diaphorase (Haverkamp & Eldred,
1988; Koch, Lambrecht, Haberecht, Redburn, & Sch-
midt, 1994; Osborne, Barnett, & Herrera, 1993; Perez,
Larsson, Alm, Andersson, & Ehinger, 1995; Vasilaki
et al., 2001). Thus, it appeared of particular interest to
examine whether SRIF acting initially via sst2A and
subsequently via the other receptor subtypes could in-
ﬂuence nitric oxide production. We investigated the
putative coexistence of the somatostatin receptor sub-
types sst1–sst5 with NADPH-diaphorase, and their
ability to inﬂuence nitric oxide levels in the retina.
sst2A was colocalized with NADPH-diaphorase on
rod bipolar cells of the rabbit retina, while sst2B is co-
localized with NADPH-diaphorase on the photorecep-
tors of the rat. These results supported for the ﬁrst time
a possible role of SRIF in the regulation of nitric oxide
in the retina (Vasilaki et al., 2001). The colocalization of
NADPH-diaphorase with the other SRIF receptor
subtypes was subsequently examined. sst1 immunoﬂuo-
rescence was colocalized with NADPH-diaphorase
mainly in the RPE, and blood vessels of the inner retina
while sst4 immunoreactivity was colocalized with
NADPH-diaphorase in ganglion cell bodies (Vasilaki
et al., 2002).
There are few studies measuring nitric oxide levels in
the retina. Neal, Cunningham, and Matthews (1998)
demonstrated that nitric oxide was selectively released
from retinal amacrine and bipolar cells in the rabbit
retina, depending on the light stimulus employed. We
conducted ex vivo experiments in retinal explants (RPE
excluded), in order to investigate directly SRIFs regu-
lation of nitric oxide production. The levels of NO in rat
retinal explants were assessed by the production of its
stable metabolites NO2 and NO

3 (NO

x ) by the method
of Grisham, Johnson, and Lancaster (1996). Somato-
statin increased NOx basal levels in a concentration-
dependent manner. To assess which somatostatin
receptor subtype was responsible for this eﬀect, selective
analogs for all the receptor subtypes were employed. In
the neural retina of the rat, sst2B (Vasilaki et al., 2001)
and sst4 (Vasilaki et al., 2002) are colocalized with
NADPH-diaphorase, and their activation would be ex-
pected to inﬂuence nitric oxide synthase. However, only
the sst2 speciﬁc analog (L-779,976; Rohrer et al., 1998)
was able to increase NOx levels. The sst2 antagonist
CYN-154806 (Feniuk, Jarvie, Luo, & Humphrey, 2000),
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supporting the pharmacological relevance of the sst2
eﬀect (Vasilaki et al., 2002).
We extended the above studies to the RPE, a mono-
layer of cells that is crucial for the integrity of the retina.
As mentioned in the previous section, Klisovic et al.
(2001) detected the sst1 and sst2 genes and immunore-
activity in cultured RPE cells. We have data to support
the presence of SRIF and its receptor subtypes sst2B and
sst5 in human RPE cell cultures. Subsequent studies also
showed the presence of NADPH-diaphorase. As in the
retinal explants SRIF, the sst2 selective analogue
MK678 increased the levels of NOx in a concentration-
dependent manner (Papadaki et al., 2002).
Nitric oxide is believed to play a variety of roles in
ocular physiology. These include the maintenance of
tight junction integrity (Zech et al., 1998), the develop-
ment of immune and inﬂammatory responses and blood
ﬂow (Cai & Boulton, 2002; Dezsi, Dornyei, Szentivanyi,
Tulassay, & Monos, 1997; Holtkamp, Kijlstra, Peek, &
de Vos, 2001). Our data suggest that somatostatin may
inﬂuence the above functions by its regulation of nitric
oxide production.4. Pharmacology of somatostatin in the retina and
putative therapeutic in retinal disease
Somatostatin has been studied as a possible thera-
peutic agent in the treatment of major retinal diseases
such as proliferative diabetic retinopathy (PDR), age-
related macular degeneration (ARMD) and cystoid
macular oedema (CME), diseases whose underlying
complications involve retinal neovascularization and
oedema that lead to blindness.
In the early nineties somatostatin and analogues were
employed in clinical studies for the treatment of PDR, a
disease whose major clinical treatment even today in-
volves laser ablation of the retinal vasculature. Soma-
tostatins therapeutic use was based on the ability of
somatostatin to inhibit growth hormone secretion, a
hormone implicated in the pathogenesis of diabetic
retinopathy (Kirkegaard, Norgaard, Snorgaard, Larsen,
& Lund-Andersen, 1990; Mallet et al., 1992; McCombe,
Lightman, Eckland, Hamilton, & Lightman, 1991).
Ocular neovascularization is strongly associated with
retinal ischemia the underlying cause of diabetic retin-
opathy (Cohen, Jasti, & Rye, 1977). Growth hormone
and the peptide growth factors such as IGF-1, ﬁbroblast
growth factor (bFGF), platelet-derived growth factor
(PDFG), and vascular derived growth factor (VEGF)
have been implicated in the development of retinal
neovascularization and the pathogenesis of ischemia
(Cai & Boulton, 2002; Dills, Moss, Klein, & Klein, 1991;
Grant, Caballero, & Millard, 1993; Hyer, Sharp,
Brooks, Burrin, & Kohner, 1989; Kirkegaard et al.,1990; Merimee, Zapf, & Froesch, 1983; Paques, Massin,
& Gaudric, 1997).
To investigate the role of the GH-IGF-somatostatin
axis in ischemia-induced retinal neovascularization
(mouse model of oxygen induced retinopathy) and its
interactions with VEGF, Smith et al. (1997) employed
mice with experimentally altered levels of GH and in
normal mice that were given the sst2 selective agonist
MK678. The conclusion was that inhibitors of GH and
IGF-1 might be useful for the inhibition of neovascu-
larization. Employing the same model of oxygen in-
duced retinopathy, Higgins, Yan, and Schrier (2002)
showed that octreotide and a new somatostatin agonist
Woc4D inhibited retinal neovascularization. In addi-
tion, Klisovic, Sall, ODorisio, Katz, and William (2001)
reported that somatostatin and octreotide inhibited the
IGF-1 mediated tyrosine autophosphorylation of the
IGF-receptor and VEGF gene transcription in RPE cells
through an sst2 mechanism. The investigators suggested
the usefulness of these agents in the treatment of PDR.
Recent clinical investigations also focus on the use of
somatostatin receptor agonists as therapeutic agents for
diabetic retinopathy (Davis, Wilson, & Grant, 2001;
Grant et al., 2000; Simo et al., 2002). Grant et al. (2000)
performed a randomised controlled clinical study and
examined the eﬃcacy of octreotide (sst2 agonist) in the
therapy of patients with severe non-proliferative and
early proliferative diabetic retinopathy. The investiga-
tors suggest that octreotide treatment in euthyroid pa-
tients may retard progression of advanced diabetic
retinopathy and may delay the time of laser surgery.
Octreotide also reduced the number of vitreous hae-
morrhages after full scatter laser coagulation in a ran-
domised trial in diabetic patients with high-risk
proliferative retinopathy (Boehm, Lang, Jehle, Feld-
man, & Lang, 2001), while Spranger et al. (2001) suggest
the use of combined treatment (somatostatin analogues
and retinal photocoagulation) of PDR.
ARMD is the major causes of blindness in people
over 50 years of age. The pathogenesis of the disease
is not understood yet newly formed vessels from the
underlying choroids grow beneath the RPE, and an-
giogenesis in choroidal neovascularization is morpho-
logically described secondary to ARMD (DAmore,
1994). Two types of the disease have been reported, the
atrophic form and the neovascular. The neovascular
form is characterized by leakage of blood or serum, the
detachment of the RPE and choroidal neovasculariza-
tion, which lead to scarring of the macula. The atrophic
form is not characterized by leakage of blood but it
involves choriocapillaries, RPE and the photoreceptors.
Both forms of the disease can lead to loss of vision. The
RPE is involved in the pathogenesis of ARMD and
there are reports to suggest that octreotide use in cho-
roidal neovascular membranes may be successful not
only because it may inhibit angiogenesis, but also due to
1812 K. Thermos / Vision Research 43 (2003) 1805–1815its antiproliferative actions (Lopez et al., 2001), which
result in inhibition of RPE proliferation and migration
(Spraul, Kaven, Kampmeier, Lang, & Lang, 1999).
In a recent review on somatostatin and its receptors in
retinal disease, Van Hagen et al. (2000) reported the
successful treatment of 13 eyes with neovascular ARMD
with the somatostatin analogue octreotide (Sandostatin-
Lar). In a pilot clinical study, Papadaki et al. (2002)
examined the role of lanreotide in the treatment of
choroidal neovascularization secondary to ARMD and
reported a trend towards stabilization of the disease.
sst2A receptors were found in newly formed endothelial
and ﬁbroblast-like cells in ﬁbrovascular choroidal neo-
vascular membranes (Lambooij et al., 2000). The pres-
ence of somatostatin and its receptors (sst2B) was
conﬁrmed in human RPE cells (Papadaki et al., 2002),
while the sst1 receptor was localized in rat RPE (Vasilaki
et al., 2002). These reports provide promising results for
the use of sst2 selective agonists, such as octreotide and
lanreotide, in the treatment of neovascular ARMD,
while the therapeutic use of sst1 agonists should also be
explored.
The RPE is also involved in cystoid macular disease,
since a dysfunctional RPE disrupts the outer blood––
retinal barrier leading to the movement of small mole-
cules, ions and ﬂuids between the retina and the choroid
and macular oedema. CME has been treated success-
fully with octreotide as reported by Kuijpers, Baarsma,
and van Hagen (1998). The integrity of both the outer
and inner blood––retinal barrier is aﬀected in CME. The
disruption of the capillary endothelium and the subse-
quent leakage from the capillaries surrounding the
macula destroys the inner blood––retinal barrier. This
may occur in response to ischemia, but also to inﬂam-
mation and other conditions. Somatostatin receptors
are diﬀerentially expressed in human vascular tissue
(Curtis et al., 2000). Studies conducted in rapidly
proliferating human retinal endothelial cells that
were stimulated by IGF-I and bFGF in vitro reported a
direct antiproliferative eﬀect of octreotide (Grant et al.,
1993).
The eﬀect of octreotide on the growth of RPE cells in
culture has also been examined in order to assess the
usefulness of somatostatin agents in proliferative vitre-
oretinopathy (Luo, Peyman, Conway, & Woltering,
1996).5. Conclusions
The aim of this review was to summarize the knowl-
edge acquired to date on somatostatin and its role in the
retina. The experimental data presented and discussed
provide solid evidence that somatostatin may act in an
autocrine or paracrine manner to inﬂuence RPE and
retinal physiology. The diﬀerential localization of itsreceptor subtypes in the RPE, photoreceptors, rod bi-
polar cells, blood vessels of the inner retina (Fig. 1)
suggest a role for somatostatin in proper RPE physio-
logy, the well being of the blood-eye barrier, retinal
blood ﬂow, and the regulation of neurotransmitter re-
lease. The correlation of somatostatins actions in the
retina with speciﬁc receptor subtypes still remains a
target of investigation, while SRIFs ability to regulate
nitric oxide production supports the strategic planning
of studies to delineate the SRIF-NO relationship and its
importance in physiological and diseased retina.Acknowledgements
This review is dedicated to the memory of Professor
Marcos Tsakopoulos, University of Athens, and Pro-
fessor Fulvia Gremo, University of Cagliary. In addi-
tion, I would like to thank my collaborators and
students Dr Anna Vasilaki, Ms Niki Mastrodimou and
Ms Despina Agouraki for their assistance and helpful
comments. Experimental work described in this manu-
script was supported by an EC contract (QLG3-CT-
1999-00908).References
Adolph, A. R. (1989). Pharmacological actions of peptides and
indoleamines on turtle retinal ganglion cells. Visual Neuroscience,
3, 411–423.
Akopian, A., Johnson, J., Gabriel, R., Brecha, N., & Witkovsky, P.
(2000). Somatostatin modulates voltage-gated Kþ and Caþþ
currents in rod and cone photoreceptors of the salamander retina.
Journal of Neuroscience, 20, 929–936.
Albers, A. R., ODorisio, S., Balster, D. A., Caprara, M., Gosh, P.,
Chen, F., Hoeger, C., Rivier, J., Wenger, G. D., ODorisio, T. M.,
& Qualman, S. J. (2000). Somatostatin receptor gene expression in
neuroblastoma. Regulatory Peptides, 88, 61–73.
Bodenant, C., Leroux, P., Gonzalez, B. J., & Vaudry, H. (1991).
Transient expression of somatostatin receptors in the rat visual
system during development. Neuroscience, 41, 595–606.
Boehm, B. O., Lang, G. K., Jehle, P. M., Feldman, B., & Lang, G. E.
(2001). Octreotide reduces vitreous hemorrhage and loss of visual
acuity risk in patients with high-risk proliferative diabetic retino-
pathy. Hormone Metabolism Research, 33, 300–306.
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., &
Guillemin, R. (1973). Hypothalamic polypeptide that inhibits the
secretion of immunoreactive pituitary growth hormone. Science,
179, 77–79.
Brecha, N., Vila, A., & Allen, J. (2002). Somatostatin subtype receptor
4 expression in mouse and rat retina. [abstract] Annual Meeting
Abstract and Program Planner. Association for Research in Vision
and Ophthalmology. Abstract 2768.
Bruno, J. F., Xu, Y., Song, J., & Berelowitz, M. (1992). Molecular
cloning and functional expression of a brain-speciﬁc somatostatin
receptor. Proceedings National Academy of Science (United States
of America), 89, 11151–11155.
Cai, J., & Boulton, M. (2002). The pathogenesis of diabetic retino-
pathy: old concepts and new questions. Eye, 16, 242–260.
Cohen, M. P., Jasti, K., & Rye, D. L. (1977). Somatomedin in insulin-
dependent diabetes mellitus. Journal of Clinical Endocrinology and
Metabolism, 45, 236–239.
K. Thermos / Vision Research 43 (2003) 1805–1815 1813Colas, B., Arilla, E., & Prieto, J. C. (1986). Characterization of
somatostatin binding sites in cytosolic fraction of pig retina.
Neuroscience Letters, 65, 193–198.
Colas, B., Valencia, A. M., Prieto, J. C., & Arilla, E. (1992).
Somatostatin binding and modulation of adenylate cyclase in
ovine retina membranes. Molecular Cell Endocrinology, 88, 111–
117.
Cristiani, R., Fontanesi, G., Casini, G., Petrucci, C., Viollet, C., &
Bagnoli, P. (2000). Expression of somatostatin subtype 1 receptor
in the rabbit retina. Investigative Ophthalmology & Visual Science,
41, 3191–3199.
Cristiani, R., Petrucci, C., Dal Monte, M., & Bagnoli, P. (2002).
Somatostatin (SRIF) and SRIF receptors in the mouse retina.
Brain Research, 936, 1–14.
Curtis, S. B., Hewitt, J., Yakubovitz, S., Anzrut, A., Hsiang, Y. N., &
Buchan, M. J. (2000). Somatostatin receptor subtype expression
and function in human vascular tissue. American Journal of
Physiology Heart Circulation Physiology, 278, H1815–H1822.
DAmore, P. A. (1994). Mechanisms of retinal and choroidal neovas-
cularization. Investigative Ophthalmology & Visual Science, 35,
3974–3979.
Davis, M. I., Wilson, S. H., & Grant, M. B. (2001). The therapeutic
problem of proliferative diabetic retinopathy targeting somato-
statin receptors. Hormone Metabolism Research, 33, 295–299.
Dawson, T. M., Bredt, D. S., Fotuhi, M., Hwang, P. M., & Snyder, S.
H. (1991). Nitric oxide synthase and neuronal NADPH diaphorase
are identical in brain and peripheral tissues. Proceedings of the
National Academy of Sciences (United States of America), 88,
7797–7801.
Dezsi, L., Dornyei, G., Szentivanyi, M. Jr., Tulassay, T., & Monos, E.
(1997). Junior Somatostatin induces vasodilatation in the cat
mesenteric artery via endothelium-derived nitric oxide and prosta-
glandins. Pﬂugers Archives-European Journal of Physiology, 433,
536–538.
Dills, D. G., Moss, S. E., Klein, R., & Klein, B. E. (1991). Association
of elevated IGF-I levels with increased retinopathy in late-onset
diabetes. Diabetes, 40, 1725–1730.
Epelbaum, J. (1986). Somatostatin in the central nervous system:
Physiology and pathological modiﬁcations. Progress in Neurobio-
logy, 27, 63–100.
Feniuk, W., Jarvie, E., Luo, J., & Humphrey, P. P. A. (2000). Selective
somatostatin sst2 receptor blockade with the novel cyclic octapep-
tide, CYN-154806. Neuropharmacology, 39, 1443–1450.
Ferriero, D. M. (1992). Developmental expression of somatostatin
receptors in the rat retina. Brain Research Developmental Brain
Research, 67, 309–315.
Florio, T., & Schettini, G. (1996). Multiple intracellular eﬀectors
modulate physiological functions of the cloned somatostatin
receptors. Journal of Molecular Endocrinology, 17, 89–100.
Fontanesi, G., Gargini, C., & Bagnoli, P. (2000). Postnatal develop-
ment of somatostatin 2A(sst2A) receptors expression in the rabbit
retina. Developmental Brain Research, 123, 67–80.
Grant, M. B., Caballero, S., &Millard, W. J. (1993). Inhibition of IGF-
I and b-FGF stimulated growth of human retinal endothelial cells
by the somatostatin analogue, octreotide: a potential treatment for
ocular neovascularisation. Regulatory Peptides, 48, 267–278.
Grant, M. B., Mames, R. B., Fizgerald, C., Hazariwala, K. M.,
Cooper-DeHoﬀ, R., Caballero, S., & Estes, K. (2000). The eﬃcacy
of octreotide in the therapy of severe nonproliferative and early
proliferative diabetic retinopathy. Diabetes Care, 23, 504–509.
Grigoryan, E., Vasilaki, A., Mastrodimou, N., & Thermos, K. (2003).
Somatostatin receptor immunoreactivity in the eye of the adult
newt (Pleurodeles waltlii Michan). Neuroscience Letters, 337, 143–
146.
Grisham, M. B., Johnson, G. G., & Lancaster, J. R. J. (1996).
Quantiﬁcation of nitrate and nitrite in extracellular ﬂuids.Methods
in Enzymology, 268, 237–246.Haverkamp, S., & Eldred, W. D. (1988). Localization of nNOS in
photoreceptor, bipolar and horizontal cells in turtle and rat retinas.
Neuroreport, 9, 2231–2235.
Helboe, L., & Moller, M. (1999). Immunohistochemical localization of
somatostatin receptor subtypes sst1 and sst2 in the rat retina.
Investigative Ophthalmology & Visual Science, 40, 2376–2382.
Helboe, L., Moller, M., Norregaard, L., Schiodt, M., & Stidsen, C. E.
(1997). Development of selective antibodies against the human
somatostatin receptor subtypes sst1–sst5. Molecular Brain Re-
search, 49, 82–88.
Higgins, R. D., Yan, Y., & Schrier, B. K. (2002). Somatostatin analogs
inhibit neonatal retinal neovascularisation. Experimental Eye
Research, 74, 553–559.
Holtkamp, G. M., Kijlstra, A., Peek, R., & de Vos, A. F. (2001).
Retinal pigment epithelium-immune system interactions: cytokine
production and cytokine-induced changes. Progress in Retina and
Eye Research, 20, 29–48.
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W.,
Humprey, P. P., OCarroll, A. M., Patel, Y. C., Schonbrunn, A.,
Taylor, J. E., & Reisine, T. (1995). Classiﬁcation and nomenclature
of somatostatin receptors. Trends in Pharmacological Sciences, 16,
86–88.
Hyer, S. L., Sharp, P. S., Brooks, R. A., Burrin, J. M., & Kohner, E.
M. (1989). Continuous subcutaneous octreotide infusion markedly
suppresses IGF-I levels whilst only partially suppressing GH
secretion in diabetics with retinopathy. Acta Endocrinology, 120,
187–194.
Johnson, J., Caravelli, M. L., & Brecha, N. (2001). Somatostatin
inhibits calcium inﬂux into rat rod bipolar cell axonal terminals.
Visual Neuroscience, 18, 101–108.
Johnson, J., Rickman, D. W., & Brecha, N. C. (2000). Somatostatin
and somatostatin subtype 2A expression in the mammalian retina.
Microscopy Research and Technique, 50, 103–111.
Johnson, J., Wong, H., Walsh, J., & Brecha, N. C. (1996). Expression
of the somatostatin receptor subtype 2A(SSTR2A) in the rabbit
retina. Abstracts Society of Neuroscience, 22, 881.
Johnson, J., Wong, H., Walsh, J., & Brecha, N. C. (1998). Expression
of the somatostatin subtype 2A receptor in the rabbit retina.
Journal of Comparative Neurology, 393, 93–101.
Johnson, J., Wu, V., Wong, H., Walsh, J. H., & Brecha, N. C. (1999).
Somatostatin receptor subtype 2A expression in the rat retina.
Neuroscience, 94, 675–683.
Kirkegaard, C., Norgaard, K., Snorgaard, O., Larsen, M., & Lund-
Andersen, H. (1990). Eﬀect of one-year continuous subcutane-
ous infusion of a somatostatin analogue, octreotide, in early
retinopathy, metabolic control and thyroid function in Type I
(insulin-dependent) diabetes mellitus. Acta Endocrinology, 122,
766–772.
Kleuss, C., Hescheler, J., Ewel, C., Rosenthal, W., Schultz, G., &
Wittig, B. (1992). Assignment of G protein subtypes to speciﬁc
receptors inducing inhibition of calcium currents. Nature (Lon-
don), 353, 43–48.
Klisovic, D. D., O Dorisio, M. S., Katz, S. E., Sall, J. W., Balster, D.,
O Dorisio, T. M., Craig, E., & Lubow, M. (2001). Somatostatin
receptor gene expression in human ocular tissues: RT-PCR and
immunohistochemical study. Investigative Ophthalmology & Visual
Science, 42, 2193–2201.
Klisovic, D. D., Sall, J. W., ODorisio, M. S., Katz, S. E., & William,
H. (2001). Somatostatin (SST) and octreotide (OCT) inhibit IGF-1
mediated tyrosine autophosphorylation of IGF-1R and induction
of VEGF gene expression in human RPE cells. Investigative
Ophthalmology & Visual Science, 42, S244.
Koch, K.-W., Lambrecht, H.-G., Haberecht, M., Redburn, D., &
Schmidt, H. H. H. W. (1994). Functional coupling of a Caþ2/
calmodulin-dependent nitric oxide synthase and a soluble guanylyl
cyclase in vertebrate photoreceptor cells. EMBO Journal, 13, 3312–
3320.
1814 K. Thermos / Vision Research 43 (2003) 1805–1815Koistinaho, J., & Sagar, S. M. (1995). Light-induced c-fos expression
in amacrine cells in the rabbit retina.Molecular Brain Research, 29,
53–63.
Kossut, M., Aldrich, L. B., Yamada, T., & Pinto, L. H. (1990). The
binding of somatostatin to the mouse retina is altered by the pearl
mutation. Brain Research, 522, 235–240.
Kossut, M., Yamada, T., Aldrich, L. B., & Pinto, L. H. (1989).
Localization and characterization of somatostatin binding sites in
the mouse retina. Brain Research, 476, 78–84.
Kuijpers, R. W., Baarsma, S., & van Hagen, P. M. (1998). Treatment
of cystoid macular edema with octreotide (Letter). New England
Journal of Medicine, 338, 624–626.
Lambooij, A. C., Kuijpers, R. W. A. M., van Lichtenauer-Kaligis, E.
G. R., Kliﬀen, M., Baarsma, G. S., van Hagen, P. M., & Mooy, C.
M. (2000). Somatostatin receptor 2A expression in choroidal
neovascularization secondary to age-related macular degenera-
tion. Investigative Opthalmology & Visual Science, 41, 2329–
2335.
Larsen, J. N., Bersani, M., Olcese, J., Holst, J. J., & Moller, M. (1990).
Somatostatin and prosomatostatin in the retina of the rat: an
immunohistochemical, in-situ hybridization, and chromatographic
study. Visual Neuroscience, 5, 441–452.
Liapakis, G., Politou, E., & Thermos, K. (1993). Solubilization of
somatostatin receptors from rabbit retina. Biochemical Pharmaco-
logy, 45, 1821–1828.
Liapakis, G., & Thermos, K. (1992). Characterization of [125I] Tyr11-
Somatostatin binding sites in the rabbit retina. Neuropeptides, 21,
13–19.
Lopez, F., Ferjoux, G., Cordelier, P., Saint-Laurent, N., Esteve, J. P.,
Vaysee, N., Buscail, L., & Susini, C. (2001). Neuronal nitric oxide
synthase: a substrate for SHP-1 inolved in sst2 somatostatin
receptor growth inhibitory signaling. Federation of American
Societies for Experimental Biology Journal, 15, 2300–2302.
Luo, Q., Peyman, G. A., Conway, M. D., & Woltering, E. A. (1996).
Eﬀect of a somatostatin analog (octreotide acetate) on the growth
of retinal pigment epithelial cells in culture. Current Eye Research,
15, 909–913.
Mallet, B., Vialettes, B., Haroche, S., Escoﬃer, P., Gastaut, P.,
Taubert, J. P., & Vague, P. (1992). Stabilization of severe
proliferative diabetic retinopathy by long-term treatment with
SMS 201-995. Diabetes Metabolism, 18, 438–444.
McCombe, M., Lightman, S., Eckland, D. J., Hamilton, A. M., &
Lightman, S. L. (1991). Eﬀect of a long-acting somatostatin
analogue (BIM23014) on proliferative diabetic retinopathy: a pilot
study. Eye, 5, 569–575.
Merimee, T. J., Zapf, J., & Froesch, E. R. (1983). Insulin-like growth
factors: studies in diabetics with and without retinopathy. New
England Journal of Medicine, 309, 527–530.
Meyerhof, W., Wylfsen, C., Schonrock, C., Fehr, S., & Richter, D.
(1992). Molecular cloning of a somatostatin-28 receptor and
comparison of its expression pattern with that of somatostatin-14
in rat brain. Proceedings of National Academy of Science (United
States of America), 89, 10267–10271.
Mori, M., Ahara, M., & Shimizu, T. (1997). Diﬀerential expression of
somatostatin receptors in the rat eye: SSTR4 is intensely expressed
in the iris/ciliary body. Neuroscience Letters, 223, 185–188.
Neal, M., Cunningham, J., & Matthews, K. (1998). Selective release of
nitric oxide from retinal amacrine and bipolar cells. Investigative
Ophthalmology & Visual Science, 39, 850–853.
OCarroll, A. M., Lolait, S. J., Konig, M., & Mahan, L. C. (1992).
Molecular cloning and expression of a pituitary somatostatin
receptor with preferential aﬃnity for somatostatin-28. Molecular
Pharmacology, 42, 939–946.
Osborne, N. N., Barnett, N. L., & Herrera, A. J. (1993). NADPH
diaphorase localization and nitric oxide synthase activity in the
retina and anterior uvea of the rabbit eye. Brain Research, 610,
194–198.Papadaki, T., Vasilaki, A., Tsilimbaris, M., Pallikaris, I., & Thermos,
K. (2002). Somatostatin regulates nitric oxide production in human
retinal pigment epithelium (RPE) cell cultures [abstract] Annual
Meeting Abstract and Program Planner [on CD-ROM]. Associa-
tion for Research in Vision and Ophthalmology. Abstract 4584.
Paques, M., Massin, P., & Gaudric, A. (1997). Growth factors and
diabetic retinopathy. Diabetes Metabolism, 23, 125–130.
Patel, Y. C., & Srikant, C. B. (1994). Subtype selectivity of peptide
analogs for all ﬁve cloned human somatostatin receptors (hsstr1-5).
Endocrinology, 135, 2814–2817.
Perez, M. T. R., Larsson, B., Alm, P., Andersson, K. E., & Ehinger, B.
(1995). Localization of neuronal nitric oxide synthase-immunore-
activity in rat and rabbit retina. Experimental Brain Research, 104,
207–217.
Petrucci, C., Resta, V., Fieni, F., Bigiani, A., & Bagnoli, P. (2001).
Modulation of potassium current and calcium inﬂux by somatost-
atin in rod bipolar cells isolated from the rabbit retina via sst2
receptors. Naunyn-Schmiedebergs Archives Pharmacology, 363,
680–694.
Reisine, T., & Bell, G. I. (1995). Molecular biology of somatostatin
receptors. Endocrine Reviews, 16, 427–442.
Rickman, D. W., Blanks, J. C., & Brecha, N. C. (1996). Somatostatin-
immunoreactive neurons in the adult rabbit retina. Journal of
Comparative Neurology, 366, 1–13.
Rohrer, S. P., Birzin, E. T., Mosley, R. T., Berk, S. C., Hutchins, S.
M., Shen, D.-M., Xiong, Y., Hayes, E. C., Parmar, R. M., Foor,
F., Mitra, S. W., Degrado, S. J., Shu, M., Klopp, J. M., Cai, S.-J.,
Blake, A., Chan, W. W. S., Pasternak, A., Yang, L., Patchett, A.
A., Smith, R. G., Chapman, K. T., & Schaeﬀer, J. M. (1998). Rapid
identiﬁcation of subtype-selective agonists of the somatostatin
receptor through combinatorial chemistry. Science, 282, 737–
740.
Rorstad, O. P., Brownstein, M. J., & Martin, J. B. (1979). Immuno-
reactive and biologically active somatostatin-like material in rat
retina. Proceedings of the National Academy of Sciences (United
States of America), 76, 3019–3023.
Rorstad, O. P., Senternman, M. K., Hoyte, K. M., & Martin, J. B.
(1980). Immunoreactive and biologically active somatostatin-like
material in the human retina. Brain Research, 199, 488–492.
Sagar, S. M. (1987). Somatostatin-like immunoreactive material in the
rabbit retina: immunohistochemical staining using monoclonal
antibodies. Journal of Comparative Neurology, 266, 291–299.
Sagar, S. M., & Marshall, P. E. (1988). Somatostatin-like immunore-
active material in associational ganglion cells of human retina.
Neuroscience, 27, 507–516.
Sagar, S. M., Marshall, P. E., & Landis, D. M. (1985). Immunore-
active somatostatin in the rat retina: light microscopic immunocy-
tochemistry and chromatographic characterization. Brain
Research, 336, 235–242.
Sagar, S. M., Rorstad, O. P., Landis, D. M. D., Arnold, M. A., &
Martin, J. B. (1982). Somatostatin-like immunoreactive material in
the rabbit retina. Brain Research, 244, 91–99.
Schindler, M., Humphrey, P. P., Lohre, S., & Friauf, E. (1999).
Immunohistochemical localization of the somatostatin sst2ðbÞ
receptor splice variant in the rat central nervous system. Neuro-
science, 90, 859–874.
Schindler, M., Kidd, E. J., Carruthers, A. M., Wyatt, M. A., Jarvie, E.
M., Sellers, L. A., Feniuk, W., & Humphrey, P. P. (1998).
Molecular cloning and functional characterization of a rat soma-
tostatin sst2(B) receptor splice variant. British Journal of Pharma-
cology, 25, 209–217.
Schindler, M., Sellers, L. A., Humphrey, P. P., & Emson, P. C. (1997).
Immunohistochemical localization of the somatostatin sst2ðAÞ
receptor in the rat brain and spinal cord. Neuroscience, 76, 225–
240.
Schulz, S., Handel, M., Schreﬀ, M., Schmidt, H., & Hollt, V. (2000).
Localisation of ﬁve somatostatin receptors in the rat central
K. Thermos / Vision Research 43 (2003) 1805–1815 1815nervous system using subtype-speciﬁc antibodies. Journal of
Physiology (Paris), 94, 259–264.
Shapiro, B., Kronheim, S., & Pinistone, B. (1979). The presence of
immunoreactive somatostatin in the rat retina. Hormone and
Metabolic Research, 11, 79–80.
Simo, R., Lecube, A., Sararols, L., Garcia-Arumi, J., Segura, R. M.,
Casamitjana, R., & Hernadez, C. (2002). Deﬁcit of somatostatin-
like immunoreactivity in the vitreous ﬂuid of diabetic patients:
possible role in the development of proliferative diabetic retino-
paty. Diabetes Care, 25, 2282–2286.
Smith, L. E. H., Kopchick, J. J., Chen, W., Knapp, J., Kinose, F.,
Daley, D., Foley, E., Smith, R. G., & Schaeﬀer, J. M. (1997).
Essential role of growth hormone in eschemia-induced retinal
neovascularization. Science, 276, 1706–1709.
Spira, A. W., Schimizu, Y., & Rorstad, O. P. (1984). Localization,
chromatographic characterization and development of somatosta-
tin-like immunoreactivity in the guinea-pig retina. Journal of
Neuroscience, 4, 3069–3079.
Spranger, J., Mohlig, M., Osterhoﬀ, M., Buhnen, J., Blum, W. F., &
Pfeiﬀer, A. (2001). Retinal photocoagulation does not inﬂuence
intraocular level of IGF-I, IGF-II and IGF-BP3 in proliferative
diabetic retinopathy-evidence for combined treatment of PDR with
somatostatin analogues and retinal photocoagulation. Hormone
Metabolic Research, 33, 312–316.
Spraul, C. W., Kaven, C. K., Kampmeier, J. K., Lang, G. K., & Lang,
G. E. (1999). Eﬀect of thalidomide, octreotide, and prednisolone on
the migration and proliferation of RPE cells in vitro. Current Eye
Research, 19, 483–490.
Tannenbaum, G. S., & Epelbaum, J. (2000). Somatostatin. In H. M.
Goodman, & J. L. Kostyo (Eds.), Handbook of physiology: Vol. V,
Section 7. The endocrine system, hormonal control of growth (pp.
221–265). NY, Oxford: Oxford University Press.
Thermos, K., He, H.-T., Wang, H.-L., Margolis, N., & Reisine, T.
(1989). Biochemical properties of brain somatostatin receptors.
Neuroscience, 31, 131–141.
Thermos, K., & Reisine, T. (1988). Somatostatin receptor subtypes in
the clonal anterior pituitary cell lines AtT-20 and GH3. Molecular
Pharmacology, 33, 370–377.
Tornqvist, K., Uddman, R., Sundler, F., & Ehinger, B. (1982).
Somatostatin and VIP neurons in the retina of diﬀerent species.
Histochemistry, 76, 137–152.
Van Hagen, P. M., Baarsma, G. S., Mooy, C. M., Ercoskan, E. M., ter
Averst, E., Hoﬂand, L. J., Lamberts, S. W. J., & Kuijpers, R. W. A.
M. (2000). Somatostatin and somatostatin receptors in retinal
diseases. European Journal of Endocrinology, 143, S43–S51.Vanetti, M., Kouba, M., Wang, X., Vogt, G., & Hollt, V. (1992).
Cloning and expression of a novel mouse somatostatin receptor
(SSTR2B). Federation of European Biochemical Societies Letters,
311, 290–294.
Vasilaki, A., Gardette, R., Epelbaum, J., & Thermos, K. (2001).
NADPH-diaphorase colocalization with somatostatin receptor
subtypes sst2A and sst2B in the retina. Investigative Ophthalmology
& Visual Science, 42, 1600–1609.
Vasilaki, A., Georgoussi, Z., & Thermos, K. (2003). Somatostatin
receptors (sst2) are coupled to Go and modulate GTPase activity in
the rabbit retina. Journal of Neurochemistry, 84, 625–632.
Vasilaki, A., Hatzilaris, E., Liapakis, G., Georgoussi, Z., & Thermos,
K. (1996). Somatostatin receptor subtypes (SSTR2) in the rabbit
retina. Abstract Society of Neuroscience, 22, 881.
Vasilaki, A., Mouratidou, M., Schulz, S., & Thermos, K. (2002).
Somatostatin inﬂuences nitric oxide production in the rat retina.
Neuropharmacology, 43, 899–909.
Vincent, S. R., & Johansson, O. (1983). Striatal neurons containing
both somatostatin- and avian pancreatic polypeptide (APP)-like
immunoreactivities and NADPH-diaphorase activity: a light and
electron microscopic study. Journal of Comparative Neurology, 217,
264–270.
White, C. A., & Chalupa, L. M. (1991). Subgroup of alpha ganglion
cells in the adult cat retina is immunoreactive for somatostatin.
Journal of Comparative Neurology, 304, 1–13.
White, C. A., Chalupa, L. M., Johnson, D., & Brecha, N. C. (1990).
Somatostatin-immunoreactive cells in the adult cat retina. Journal
of Comparative Neurology, 293, 134–150.
Yamada, T., Marshak, D., Basinger, S., Walsh, J., Morley, J., & Stell,
W. (1980). Somatostatin-like immunoreactivity by frog retinas
in vitro. Journal of Neurochemistry, 39, 1539–1546.
Yamada, Y., Post, S. R., Wang, K., Tager, H., Bell, G., & Seino, S.
(1992). Cloning and functional characterization of a family of
human and mouse somatostatin receptors expressed in brain,
gastro-intestinal tract, and kidney. Proceedings of the National
Academy of Sciences (United States of America), 89, 251–255.
Yamaguchi, K., Gaur, V. P., Spira, A. W., & Turner, J. E. (1990).
Cellular localization of somatostatin mRNA in rat retina. Neuro-
peptides, 17, 13–16.
Zalutsky, R. A., & Miller, R. F. (1990). The physiology of somato-
statin in the rabbit retina. Journal of Neuroscience, 10, 383–393.
Zech, J. C., Pouvreau, I., Cotinet, A., Goureau, O., Li Varlet, B., & De
Kozak, Y. (1998). Eﬀect of cytokines and nitric oxide on tight
junctions in cultured rat retinal pigment epithelium. Investigative
Ophthalmology & Visual Sciences, 39, 1600–1608.
